258 related articles for article (PubMed ID: 28393712)
1. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
Ohno Y; Tokudome K
CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
[TBL] [Abstract][Full Text] [Related]
2. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
Tokudome K; Shimizu S; Serikawa T; Ohno Y
Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
[TBL] [Abstract][Full Text] [Related]
3. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
[TBL] [Abstract][Full Text] [Related]
4. A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.
Tokudome K; Okumura T; Terada R; Shimizu S; Kunisawa N; Mashimo T; Serikawa T; Sasa M; Ohno Y
Front Pharmacol; 2016; 7():210. PubMed ID: 27471467
[TBL] [Abstract][Full Text] [Related]
5. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
Shi J; Zhou F; Wang LK; Wu GF
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
[TBL] [Abstract][Full Text] [Related]
6. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Serajee FJ; Huq AM
Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study.
Pazarlar BA; Madsen CA; Oyar EÖ; Eğilmez CB; Mikkelsen JD
Epilepsy Res; 2022 Jul; 183():106926. PubMed ID: 35526328
[TBL] [Abstract][Full Text] [Related]
9. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
[TBL] [Abstract][Full Text] [Related]
10. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
11. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats.
Wang L; Shi J; Wu G; Zhou F; Hong Z
Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164
[TBL] [Abstract][Full Text] [Related]
12. Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling.
Ohno Y; Ishihara S; Terada R; Kikuta M; Sofue N; Kawai Y; Serikawa T; Sasa M
Biochem Biophys Res Commun; 2009 Dec; 390(3):415-20. PubMed ID: 19751703
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain.
Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G
Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710
[TBL] [Abstract][Full Text] [Related]
14. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
[TBL] [Abstract][Full Text] [Related]
16. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
[TBL] [Abstract][Full Text] [Related]
18. Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain.
Mikkelsen JD; Aripaka SS; Bascuñana P; Bankstahl M; Bankstahl JP; Pazarlar BA
Neuroscience; 2022 Sep; 499():142-151. PubMed ID: 35878719
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
[TBL] [Abstract][Full Text] [Related]
20. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
